Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A high resolution genome wide array CGH led us to identify the first case of a de novo constitutional deletion confined to the FBXW7 gene, a well known tumor suppressor, in a patient with a syndromic phenotype characterized by focal segmental glomerulosclerosis and multiple primary early/atypical onset tumors, including Hodgkin's lymphoma, Wilms tumor and breast cancer.
|
26482194 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have first evaluated 141 breast carcinomas for genome-wide copy number changes by chromosomal CGH and showed that 1q21 and 1q32 were the two chromosome bands with most frequent genomic copy number gains.
|
23329352 |
2013 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We concluded that using CGH results to focus on a sub-set of families for sequencing analysis did not enable us to identify a common genetic change responsible for the aggregation of breast cancer in these families.
|
23383274 |
2013 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this study was CGH array profiling of breast cancer from Malian women in order to define differences with those from USA.
|
22999459 |
2013 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis.
|
23186559 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
|
20614180 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a custom CGH-like oligonucleotide array to measure the global microsatellite content in the genomes of 72 cancer, cancer-free, and high risk patient and cell line samples (56 germline DNA and 16 in tumor or tumor cell line DNA) we found a unique, reproducible, and statistically significant pattern of 18 motif-specific microsatellite families (out of 962 possible 1-6 mer repeats) in breast cancer patient germline and tumor DNA, but not in germline DNA of cancer-free volunteer controls or in breast cancer patients with BRCA1/2 mutations.
|
21319262 |
2011 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Array CGH is potentially useful in the identification of genomic alterations from primary tumor and blood in breast cancer patients.
|
20409316 |
2010 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The position of our FISH probe and data of a previously performed high-resolution CGH study in the breast cancer cell line SK-BR-3 involve TCEB1 and TMEM70 as new possible candidate oncogenes at 8q21 in breast cancer.
|
20139910 |
2010 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
|
18704682 |
2009 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of the b-HCG/LH/LH-R system in breast cancer is conflicting.
|
18758818 |
2009 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event.
|
19448591 |
2009 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
|
19670217 |
2009 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of a recent mRNA expression profiling study in breast cancer (n = 100 cases) and an array-CGH screen in medulloblastomas (n = 102 cases), revealed downregulation in 40% and genomic loss in 11% of cases, respectively.
|
18058815 |
2008 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review we will address this question and discuss the different undertaken approaches used in identifying new breast cancer susceptibility genes, such as (genome-wide) linkage analysis, CGH, LOH, association studies and global gene expression analysis.
|
17498966 |
2007 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity.
|
16964389 |
2006 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used the complementary techniques of microsatellite-based LOH, high-density FISH, and conventional CGH on 6 breast cancer cell lines (MCF7, SKBR3, T47D, MDA MB453, BT549, and BT474) to investigate the molecular cytogenetic changes occurring on chromosome 8 during tumorigenesis, with particular emphasis on 6 potential TSGs on 8p.
|
15993269 |
2005 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays.
|
15682439 |
2005 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that CGH analysis of multiple breast carcinomas followed by unsupervised hierarchical clustering of the genomic imbalances is more reliable than previous criteria to determine the tumours' clonal relationship in individual patients, that most ipsilateral breast carcinomas arise through intramammary spreading of a single breast cancer, and that most patients with bilateral breast carcinomas have two different diseases.
|
15266323 |
2004 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate genome-wide retention of allelic differences following balanced-PCR amplification of DNA from breast cancer and normal human cells and genomic profiling by array-CGH (cDNA arrays, 100 kb resolution) and by real-time PCR (single gene resolution).
|
15155823 |
2004 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The entire sequence of mRNA encoding for hCG receptor was detected in MCF-7 but not in MB231 breast cancer cell line.
|
12602911 |
2003 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Initial applications of array CGH to the analysis of breast cancer, and the mechanisms by which the particular types of copy number changes might arise are discussed.
|
12755488 |
2003 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we illustrate how the combination of three different microarray technologies, cDNA, CGH, and tissue microarrays, makes it possible to directly identify genes involved in chromosomal rearrangements in cell line model systems and then rapidly explore their significance as potential diagnostic and therapeutic targets in human primary breast cancer progression.
|
11562182 |
2001 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty formalin-fixed, paraffin-embedded breast carcinomas were investigated by fluorescence in situ and comparative genomic hybridization (FISH, CGH) as well as by immunohistochemistry (IHC) using Dako-HercepTest and CB11 antibody (Ventana).
|
11119122 |
2000 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification.
|
10597224 |
1999 |